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Bullous pemphigoid, the most common autoimmune
subepidermal bullous disorder, is associated with auto-
antibodies targeting antigenic sites clustered within the
extracellular domain of BP180. To investigate epitope
and subclass speci¢city of autoantibodies in bullous
pemphigoid, we developed an enzyme-linked immu-
nosorbent assay utilizing baculovirus-expressed recom-
binant forms of the NH2- and COOH-terminal regions
of the extracellular domain of BP180 and examined sera
obtained from patients with active bullous pemphigoid
(n¼116) and controls (n¼100). Ninety-three (80%) and
54 (47%) of the 116 bullous pemphigoid sera recognized
the NH2- and COOH-terminal regions, respectively, of
the extracellular domain of BP180. Detailed analysis de-
monstrates that (i) this novel enzyme-linked immuno-
sorbent assay is highly speci¢c (98%) and sensitive
(93%) as 108 of 116 bullous pemphigoid sera reacted
with at least one of the baculovirus-derived recombi-
nants, (ii) in active bullous pemphigoid, autoantibodies
against the NH2-terminus of the extracellular domain
of BP180 were predominantly of the IgG1 class, whereas
a dual IgG1 and IgG4 response to this region was related
to a more severe skin involvement, (iii) autoreactivity
against both the NH2- and COOH-terminal regions
was more frequently detected in patients with mucosal
lesions, and (iv) levels of IgG (and IgG1) against the
NH2-terminal, but not against the COOH-terminal
portion of the extracellular domain of BP180, re£ected
disease severity indicating that autoantibodies against
the NH2-terminus are critical in the pathogenesis of
bullous pemphigoid. In conclusion, this novel en-
zyme-linked immunosorbent assay represents a highly
sensitive and speci¢c assay for rapid diagnosis of bullous
pemphigoid and related disorders and may provide pre-
dictive parameters for the management of bullous
pemphigoid patients. Key words: adhesion molecules/
autoantibodies/autoimmunity/BP180/disease activity/hemides-
mosome. J Invest Dermatol 119:1065 ^1073, 2002
B
ullous pemphigoid (BP) is an autoimmune blistering
disorder of the skin that usually a¡ects the elderly.
The disease is associated with tissue-bound and circu-
lating IgG autoantibodies directed against compo-
nents of the epidermal basement membrane zone
( Jordon et al, 1967). Clinically, BP is characterized by generalized
tense subepidermal blisters arising on apparently normal or
erythematous skin with involvement of mucous membranes in
20%^30% of cases (Lever, 1953). Previous studies have demon-
strated that BP autoantibodies predominantly recognize BP230
(BPAG1) and BP180 (BPAG2 or type XVII collagen) (Labib et al,
1986; Stanley et al, 1988; Giudice et al, 1992), two structural com-
ponents of hemidesmosomes. Hemidesmosomes are multiprotein
junctional complexes that promote attachment of basal keratino-
cytes to the underlying basement membrane zone (reviewed in
Borradori and Sonnenberg, 1999). BP230, an entirely cytoplasmic
protein belonging to the plakin family, is involved in the
anchorage of intermediate ¢laments to the basal cell surface
(reviewed in Ruhrberg and Watt, 1997). In contrast, BP180 is a
transmembrane protein with a type II orientation. Its large extra-
cellular portion consists of 15 interrupted collagenous sub-
domains (Giudice et al, 1992; Hopkinson et al, 1992). It serves as a
cell surface receptor (Giudice et al, 1992; Hopkinson et al, 1992)
and plays an important role in the maintenance of epidermal^
stromal adhesion (reviewed in Borradori and Sonnenberg, 1999).
This notion is supported by the observation that mutations in
the BP180 gene (COL17A1) are the cause of a clinical variant of
non-Herlitz junctional epidermolysis bullosa, a congenital dis-
order characterized by skin fragility and blistering (reviewed in
Pulkkinen and Uitto, 1998).
Recently, strong evidence has been provided that autoantibo-
dies to BP180 play a key role in subepidermal blister formation
in BP patients. In a passive transfer model, rabbit antibody raised
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against the murine homolog of the human immunodominant
region of BP180, the NC16A domain, were able to induce sub-
epidermal blister formation, reproducing all key features of BP
(Liu et al, 1993). Furthermore, it has been found that the serum
levels of IgG autoantibodies directed against the extracellular do-
main (ECD) of BP180 were related to the severity of BP (Haase
et al, 1998; Schmidt et al, 2000).
Autoantibodies from patients with BP and some closely related
autoimmune bullous disorders, such as gestational and cicatricial
pemphigoid, have been found to predominantly recognize two
major antigenic regions of the ECD of BP180. Speci¢cally, the
NC16A subdomain, a region adjacent to the membrane spanning
domain of BP180, harbors major epitopes recognized by almost
all sera from patients with BP as well as gestational pemphigoid,
a blistering disorder associated with autoimmunity against BP180
that occurs during pregnancy (Giudice et al, 1993; Matsumura
et al, 1996). In these patients, reactivity with the ECD of BP180
can be almost completely abolished by pre-adsorption of IgG
with recombinant NC16A protein (Zillikens et al, 1997a; Hata
et al, 2000; Lin et al, 2000). Second, the COOH-terminal region
of the ECD of BP180 has been shown to be recognized by ap-
proximately one-third of BP sera (Murakami et al, 1998; Nakatani
et al, 1998) as well as by sera from a subset of patients with cicatri-
cial pemphigoid (Balding et al, 1996; Bedane et al, 1997; Murakami
et al, 1998; Nie and Hashimoto, 1999), a chronic autoimmune blis-
tering disorder characterized by predominant involvement of
mucosal surfaces with scarring.
The purpose of this study was to develop a sensitive and
highly speci¢c in vitro assay for the detection of circulating auto-
antibodies in BP utilizing baculovirus-derived recombinants of
the NH2- and COOH-terminal regions of the ECD of BP180.
The baculovirus expression system has proved to be extremely
useful for the production of recombinant proteins retaining
many of the post-translational modi¢cations of the native pro-
teins (Kidd and Emery, 1993). Because of the putative key role of
BP180 in disease initiation, we assessed the reactivity against these
two BP180 recombinant proteins in serum samples obtained
from BP patients and from a control group and further character-
ized the epitope speci¢city as well as the isotype distribution of
the autoantibody response to BP180. Furthermore, we investi-
gated the potential relationship between the autoantibody pro¢le
of these BP sera and the clinical phenotype and severity of BP.
MATERIALS AND METHODS
Patients and control sera Serum samples were obtained from patients
with clinically active BP (n¼116), BP patients in remission (n¼ 6), and
control donors; the latter included patients with pemphigus vulgaris
(n¼ 28) and healthy volunteers (normal human sera, n¼ 72). All patients
and volunteers gave written consent to participate in this study.
In the group of patients with active BP, sera were taken before
immunosuppressive treatment in 99 patients, but 17 patients with chronic
BP had already received systemic immunosuppressive treatment. Diagnosis
of BP was based on the following criteria: (i) typical clinical presentation
with tense cutaneous blisters (including 16 cases with additional
involvement of mucous membranes without scarring); (ii) histopathologic
evidence of subepidermal blister formation; (iii) linear IgG and/or C3
deposits at the dermo-epidermal junction of perilesional skin by direct
immuno£uorescence; and (iv) IgG-positive indirect immuno£uorescence
on saline-separated human skin. Control sera were collected from
randomly chosen healthy individuals who had no history of bullous skin
disorder and from 28 pemphigus vulgaris patients whose sera showed
intercellular IgG reactivity on monkey esophagus or human skin and
also reacted with recombinant desmoglein 3 by enzyme-linked immuno-
sorbent assay (ELISA).
To investigate the relationship between autoantibody pro¢les of the BP
sera and the clinical phenotype, sera from patients with active BP were
compared to those of patients in remission; ¢ve of the latter patients had
received systemic immunosuppressive treatment, and one patient received
no therapy. A total of 114 BP patients (i.e., 108 patients with active BP and
six patients in remission) were clinically well characterized with regard to
disease severity and the duration of disease (Table III). Disease severity was
classi¢ed according to the extent and number of blisters: 0, no skin lesions;
1, localized disease (few bullae or bullae at limited areas of the body);
2, generalized disease. The clinical stage of BP was de¢ned as ‘‘acute’’
(duration r3 mo) or ‘‘chronic’’ (duration Z3 mo with persisting bullae
or erosions). ‘‘Remittent’’ was de¢ned by the absence of skin lesions for
more than 1 mo. Patient and control sera were stored at ^201C prior to
analysis. Sera from 95 BP patients with IgG against the NH2-terminus of
the BP180 ectodomain (Tables IV,V) and 48 sera reactive to the COOH-
terminus (Table VI) were analyzed with regard to the antibody levels and
isotype distribution of BP180-reactive IgG, disease activity, duration, and
mucosal involvement.
Expression and puri¢cation of recombinant BP180 proteins The
recombinant proteins BP180-N (NC16A domain and the collagenous
Col15 domain of BP180) and BP180-C (COOH-terminal domains NC3^
NC1 of BP180) are linked to glutathione-S-transferase (GST) and 6xHis
tag (Fig 1) and were produced in a baculovirus expression system as
described below. The generation of cDNAs encoding for human BP180
has been described previously (Borradori et al, 1997). These cDNAs were
used as a template to amplify by polymerase chain reaction (PCR)
truncated variants of BP180 using Pfu DNA polymerase following the
manufacturer’s instructions (Stratagene, La Jolla, CA). Forward primers
contained an EcoR I site and reverse primers contained either an EcoR I
or a Not I site adjacent to the sequence homologous to the desired BP180
sequence. The cDNA fragments were subcloned into the pAcGHLT-A
baculovirus transfer vector (Pharmingen, San Diego, CA) by ligation of
double digested PCR fragments into the correspondingly cut vectors.
Correctness of both constructs was veri¢ed by nucleotide sequencing.
pAcGHLT-A vectors were cotransfected with BaculoGold DNA
(Pharmingen) into Sf21 insect cells and recombinant baculoviruses were
ampli¢ed using a previously described protocol (Amagai et al, 1994).
The recombinant BP180 proteins and the GST/6xHis control protein
(generated by cotransfection of an empty pAcGHLT-A vector) were
expressed in Sf21 cells as previously described (Haase et al, 1998).
Recombinant BP180 proteins were puri¢ed as follows: 3 d after infection,
10106 baculovirus-infected insect cells were suspended in 1ml of ice-
cold lysis bu¡er (Pharmingen), incubated for 1 h at 41C, and then
centrifuged (2000 g, 15 min). Solubilized proteins were puri¢ed by
a⁄nity chromatography over Nickel-NTA agarose (Quiagen, Hilden,
Germany) using the batch method according to the manufacturer’s
protocol. The BP180 recombinant BP180-N and the GST/6xHis control
protein were puri¢ed under native conditions, whereas puri¢cation of
BP180-C was performed under denaturing conditions by adding 6 M
guanidine hydrochloride to the lysis bu¡er and 8 M urea to washing and
elution bu¡ers. Puri¢ed proteins were ¢nally dialyzed against phosphate-
bu¡ered saline (PBS) (pH 7.5) at 41C for 48 h (BP180-N, GST/6xHis) or
gradually dialyzed against PBS supplemented with 8 M to 3 M urea
(BP180-C). A⁄nity-puri¢ed BP180 proteins were stored in aliquots at
801C. Protein concentrations were determined with a commercial kit
(DC Protein Assay, Bio-Rad, Munich, Germany) according to a modi¢ed
protocol by Lowry. BP180-N and BP180-C were fractionated by 10%
sodium dodecyl sulfate polyacrylamide gel electrophoresis and visualized
Figure 1. Scheme of the BP180 recombinants utilized in this ELISA
study. (A) BP180 is a type II transmembrane protein containing an intra-
cellular domain (ICD), a transmembrane domain, and an ECD with 15 in-
terrupted collagenous domains.The extracellular NC16A domain is located
adjacent to the plasma membrane. The recombinant BP180 fusion proteins
are composed of a 6xHis and a GST-tag at the NH2 end, followed by the
antigenic epitopes at the COOH-terminus. BP180-N contains the NC16A
domain and the collagenous domain Col15 (aa 490^811), and BP180-C en-
compasses the COOH-terminal domains NC3^NC1 (aa 1351^1497). (B)
The puri¢ed BP180 recombinants were transferred to nitrocellulose mem-
branes and detected with a monoclonal anti-GST antibody. Lane 1, BP180-
N; lane 2, BP180-C; lane 3, GST/6xHis. Numbers shown on the left refer to
molecular weight marker.
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by Coomassie staining and Western blot with a monoclonal mouse anti-
GST antibody (1:2000, clone GST3-4C, Zymed, San Francisco, CA) to
verify molecular weight and immunoreactivity of the recombinant BP180
proteins (Fig 1).
ELISA utilizing BP180 recombinants Optimal conditions for the
ELISA were established by various chessboard titrations following
published guidelines (Kemeny, 1991). The a⁄nity-puri¢ed recombinants
of BP180 were immobilized on 96-well polystyrene plates (Maxisorb
Immunoplate, Nunc, Wiesbaden, Germany) by coating each well with
0.5 mg of BP180-N, 0.5 mg of BP180-C, or a molar equivalent amount of
the control protein GST/6xHis in 100 ml of 0.1M bicarbonate bu¡er, pH
9.8, at 41C for 5 h. An incubation time of 5 h was arbitrarily chosen and
worked well in the laboratory routine; shorter incubation times led to a
reduced sensitivity of the assay. ELISA plates were then washed ¢ve times
with TBST (TBS pH 7.5 with 0.05% Tween 20; Merck, Nˇrnberg,
Germany) and blocked for 2 h with 100 ml of 5% skimmed milk powder
in TBST at room temperature. Patients’ and control sera diluted 50-fold in
blocking bu¡er were added to the wells in duplicate. After an incubation
period of 2 h at room temperature and consecutive washes as above, wells
were reacted with alkaline phosphatase (AP) labeled goat antihuman IgG
(g) (1:6000, Kirkegaard and Perry, Gaithersburg, MD), monoclonal
biotinylated mouse antihuman IgG1 (1:800, clone HP6069) or monoclonal
biotinylated mouse antihuman IgG4 (1:500, clone HP6025) (both Zymed,
San Francisco, CA), biotinylated mouse antihuman IgE (1:500, Zymed) or
peroxidase-conjugated sheep antihuman IgA (1:5000, The Binding Site,
Birmingham, U.K.) for 1^2 h. After incubation of biotinylated antibody
for 1 h, wells were washed as above and incubated with streptavidin^AP
(ZyMAX, Zymed) diluted at 1:2000 in TBS for 1 h at room temperature.
After another series of washes, 100 ml of p-nitrophenylphosphate
(Kirkegaard and Perry) or the peroxidase substrate 2,20 -azino-bis(3-ethyl-
benzthiazoline-6-sulfonic acid) (Sigma, Deisenhofen, Germany) were
added to the wells and optical density (OD) was measured at 405 nm
when a de¢ned patient serum (positive reference control) reached an OD
of 1.0 as determined with aWallac 1420 microplate reader (Wallac, Freiburg,
Germany).
All extinction data were standardized based on the positive and negative
internal standards, which were set to 1 and 0 OD units, respectively. The
background reactivity of IgG to the control protein GST/6xHis was
subtracted from the mean OD values obtained with BP180-N and BP180-
C proteins. For the detection of IgG1, IgG4, IgE, and IgA reactivity to
BP180, the GST/6xHis control protein was not used routinely, because a
relevant total IgG reactivity against GST/6xHis had not been detected in
any of the sera by ELISA. To evaluate plate-to-plate variability, each plate
included identical internal controls (two positive sera, one control serum).
The speci¢city of serum reactivity to BP180-N and BP180-C was veri¢ed
by immunoadsorption of sera with these BP180 recombinants prior to
ELISA (‘‘inhibition ELISA’’), which led to a signi¢cant decrease of serum
reactivity to these particular BP180 recombinants. A total of 4 mg of
BP180-N, BP180-C, or GST/6xHis proteins was added to nitrocellulose
membranes, followed by two washes with TBST for 10 min.
Subsequently, membranes were blocked with TBST containing 5%
skimmed milk powder for 1 h at room temperature and then incubated
with sera diluted 50-fold in blocking bu¡er overnight at 41C. Patient and
control sera before and after pre-adsorption were then reacted with GST/
6xHis and the BP180 recombinants on ELISA and IgG reactivity was
detected as described above.
Statistical analysis Statistical analysis was performed using SPSS 10.0
(SPSS, Chicago, IL). Receiver operating characteristic (ROC) curves were
used to evaluate the ability of the ELISA to detect autoantibodies against
the NH2- and COOH-terminal domains of the ECD of BP180. The areas
under the curves (AUC) are reported with their 95% con¢dence
interval (95%-CI). The Youden index ( J¼ sensitivityþ speci¢city1)
was used to select the best cut-o¡ values. To assess the reproducibility of
the ELISA results, coe⁄cients of variance were calculated for a BP
reference serum with an intermediate OD reading. The interassay
variability of the OD405 readings for the di¡erent ELISAs ranged
between 6.9% and 12.6% depending on the investigated BP180
recombinant and the Ig subclass.
Disease activity and disease duration were compared with ELISA values
using multivariate analysis of covariance additionally consisting of age and
sex. To enhance the assumption of normality, ELISA values were log-
transformed. The independence of the distribution of epitope and Ig
subtype speci¢c autoantibody and the clinical phenotype was tested by
Fisher’s exact test. po0.05 was considered statistically signi¢cant. Values
are expressed as geometric mean7geometric standard error.
RESULTS
IgG reactivity of BP sera against the NH2- and COOH-
terminal regions of the ECD of BP180 is detected in the
majority of BP sera using a novel ELISA Sera from patients
with active BP (n¼116), from normal volunteers (n¼ 72), and
from patients with pemphigus vulgaris (n¼ 28) were tested
against the BP180 recombinants, BP180-N and BP180-C, that
were immobilized onto ELISA microtiter plates. These BP180
recombinants presumably possessed a conformation identical or
similar to the native BP180 protein (Fig 2). Based on the
maximization of the Youden index (sensitivityþ speci¢city1),
the cut-o¡ point for the ELISAwith BP180-N protein was set at
0.149 OD units, which corresponds to a Youden index of 0.792.
Reactivity to BP180-C was considered positive when the OD of
the sera exceeded 0.065 units (Youden index¼ 0.436). The
diagnostic accuracy of each test, as determined by ROC curves,
is represented by the area under the curve (AUC (95%-CI)),
which was 0.925 (0.887^0.963) for the BP180-N and 0.796 (0.737^
0.855) for the BP180-C ELISA (Fig 3). Using the selected cut-o¡
values, 93 (80%) and 54 (47%) of 116 BP sera exhibited speci¢c
reactivity with BP180-N and BP180-C, respectively (Fig 3).
One (speci¢city 99%) and three (speci¢city 97%) of the control
Figure 2. Rabbit sera raised against BP180-N and BP180-C bind to
the epidermal site of saline-split human skin. Rabbits were immu-
nized with BP180-N and BP180-C, respectively, and sera were collected
12 wk after immunizations. (A) Sera from rabbits raised against BP180-N
(NH2-terminus of the BP180 ectodomain) immunoblotted BP180-N pro-
tein and cross-reacted with the epidermal roof of saline-split human skin.
(B) Accordingly, rabbit sera raised against BP180-C (COOH-terminus of
the BP180 ectodomain) immunoblotted BP180-C protein and cross-re-
acted with the epidermal roof of saline-split human skin. Lane 1, BP180-
N; lane 2, BP180-C. Numbers shown on the left refer to molecular weight
marker.
BP180-ELISA AND BULLOUS PEMPHIGOID 1067VOL. 119, NO. 5 NOVEMBER 2002
sera yielded marginal OD readings against BP180-N and BP180-
C, respectively.
A total of 108 of 116 BP sera (93%) reacted with at least one of
the recombinant BP180 proteins as summarized in Table I. One
of the eight (7%) negative sera showed IgG reactivity with the
entire ECD of BP180, as determined by ELISA with the BP180
recombinant BV13 (Haase et al, 1998). None of these eight sera
reacted with the intracellular domain of BP180 as assessed by
immunoblotting utilizing a recombinant form of BP180
(Perriard et al, 1999), whereas four other sera immunoblotted the
COOH-terminal region of BP230 (Skaria et al, 2000) and one
serum showed IgG reactivity to laminin 5. The remaining two
sera were not further classi¢ed despite IgG reactivity with
saline-separated human skin (Fig 4).
To con¢rm the speci¢city of circulating antibody against the
fusion proteins BP180-N and BP180-C, six BP sera reactive to
these recombinants were examined by inhibition ELISA as
described above. IgG reactivity of these sera to BP180-N, but
not to BP180-C, was signi¢cantly reduced by pre-absorption
with BP180-N and vice versa. Pre-absorption with GST/6xHis
did not signi¢cantly alter the reactivity of these sera with
BP180-N and BP180-C (data not shown).
IgG1 and IgG4 are the predominant Ig classes against
the NH2- and COOH-terminal regions of the ECD of
BP180, whereas IgE and IgA antibodies are rarely detected
Further characterization of the BP180-reactive BP sera was
performed by Ig subclass analysis. Subclass speci¢city against the
BP180 recombinants was determined in 93 BP sera reactive with
BP180-N, 54 sera reactive with BP180-C, and in 100 control sera.
IgG1 reactivity to BP180-N was found in 79 of 93 (85%) and
IgG4 reactivity in 43 of 93 (46%) of the BP180-N-reactive BP
sera (Fig 5A). In 42 of 93 (45%) sera, antibodies of the IgG1 class
were detected exclusively, whereas six of 93 (6%) sera showed an
isolated IgG4 response to BP180-N. In contrast, the majority of
BP sera reactive with the COOH-terminus (BP180-C) showed a
dual IgG1 and IgG4 response: 41 of 54 (76%) and 37 of 54 (69%)
BP sera contained IgG1 and IgG4 antibodies against BP180-C,
respectively (Fig 5B), and autoantibody reactivity to BP180-C
was restricted to the IgG1 class in 10 of 54 (19%) and to IgG4 in
seven of 54 (13%) BP patients. Two of 100 (2%) control sera
reached OD values slightly above the cut-o¡ points, resulting in
a speci¢city of the ELISA of 98% (Table II). The 116 BP and 100
control sera were also analyzed with regard to IgE and IgA
reactivity against the NH2- and COOH-terminus of the ECD
Figure 3. Detection of IgG against the NH2-terminal and COOH-
terminal regions of the BP180 ectodomain in BP sera. Detection of
serum IgG against the NH2-terminus (BP180-N, top panel ) and the
COOH-terminus (BP180-C, bottom panel ) of the BP180 ectodomain shown
as scatter plots and ROC curves (insets). Sera of patients with active BP
(n¼116) and 100 control sera (NHS, normal human sera; PV, pemphigus
vulgaris sera) were incubated with 0.5 mg of immobilized BP180-N and
BP180-C proteins. IgG binding was detected with an AP-labeled antihu-
man IgG antibody. Each sample was run in duplicate and plotted dots re-
present the mean of the OD reading at 405 nm of a serum sample with
BP180 recombinants normalized against IgG reactivity with recombinant
GST/6xHis. The solid lines indicate the cut-o¡ values as evaluated by max-
imization of theYouden index.
Table I. Sensitivity of IgG analysis of BP sera by the BP180
ELISA
BP180-Na BP180-Cb BP serac %
þ  54 46.5
þ þ 39 33.5
 þ 15 13
  8 7
Total 116 100
aNH2-terminus (NC16A and Col15) of the ECD of BP180.
bCOOH-terminus of the ECD of BP180.
cTotal of 116 BP sera studied.
Figure 4. Serologic classi¢cation of the investigated BP sera. The
sera of all 116 BP patients with clinically active disease were positive by in-
direct immuno£uorescence on saline-split human skin. All the BP sera
showed IgG reactivity with the epidermal side (and dermal side in two
sera) of the saline-split human skin. Reactivity against the BP180 ectodo-
main (BP180-N, BP180-C, or BV13), the COOH-terminus of BP230, and
laminin 5 was determined by ELISAwith recombinant (BP180-N, BP180-
C, BV13, BP230) and native (laminin 5) proteins, respectively.
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of BP180. IgE antibodies against BP180-N were detected in six of
116 (5%) sera and IgA against BP180-N in four of 116 (3%) BP
sera (Fig 5). IgE and IgA reactivity to BP180-C was detected in
three of 116 (3%) and two of 116 (2%) BP sera, respectively. None
of the control sera exceeded the cut-o¡ values for IgE and IgA
reactivity (Table II). Interestingly, one BP serum contained IgA
antibody only against BP180-N in addition to IgG antibody
against BP180-C, whereas another patient showed exclusive IgE
autoreactivity against BP180-C in addition to IgG reactivity
against BP180-N. None of the BP patients showed a dual IgE
and IgA response. Seven of the nine (78%) sera containing IgE
antibody against either BP180-N or BP180-C were from BP
patients with extensive skin involvement.
An antibody response against both the NH2- and COOH-
terminal domains of the ECD of BP180 occurs more
frequently in patients with mucous membrane involvement
IgG autoreactivity to distinct regions of BP180 may be related to
a particular clinical phenotype of BP. As 114 of the investigated
122 BP patients were very well characterized with regard to
clinical phenotype, the sera from these 114 patients were divided
into four groups according to their reactivity against (i) the
NH2-terminus (BP180-N), (ii) the COOH-terminus (BP180-C),
(iii) both the NH2- and COOH-terminus of the ECD of BP180,
or (iv) none of the BP180 recombinants. Distribution of IgG
reactivity to the BP180 recombinants was then compared with
regard to (i) disease severity, (ii) disease duration, and (iii)
mucosal involvement, using Fisher’s exact probability test
(Table III). Although the severity and duration of BP did not
appear to be related to reactivity against distinct regions of
the ECD of BP180, a relationship could be observed between
the presence of mucosal lesions and the pro¢le of the
autoantibody response (p¼ 0.021). The majority of patients
without mucosal involvement (54 of 98; 55.1%) had circulating
antibodies reactive only with the NH2-terminus, whereas more
patients with mucosal involvement (nine of 16; 56.2%) had IgG
autoantibodies against both the NH2- and COOH-terminus of
the ECD of BP180. In contrast, there was no association
between autoantibodies against the COOH-terminus only and
the presence of mucosal lesions (Table III).
Figure 5. Distribution of IgG1, IgG4, IgE, and IgA reactivity of BP
sera against the NH2- and COOH-terminal regions of the BP180
ectodomain. BP sera and control sera (data not shown) were incubated
with immobilized recombinant BP180-N (top panel ) and BP180-C (bottom
panel ) and probed with one of a series of AP- or peroxidase-conjugated
antibody speci¢c for IgG1, IgG4, IgE, and IgA (as indicated on the horizon-
tal axes). Each sample was run in duplicate and results are expressed as
mean of OD reading at 405 nm. Solid lines indicate the cut-o¡ values as
evaluated by maximization of theYouden index (seeTable II).
Table II. Cut-o¡ values for Ig subtype analysis by the BP180
ELISA
BP180
recombinant Ig subclass Cut-o¡ (OD405) Youden
c
BP180-Na IgG1 0.340 0.829
IgG4 0.188 0.442
IgE 0.262 0.052
IgA 0.268 0.034
BP180-Cb IgG1 0.271 0.739
IgG4 0.222 0.665
IgE 0.342 0.026
IgA 0.173 0.017
aNH2-terminus of the ECD of BP180.
bCOOH-terminus of the ECD of BP180.
cYouden index (sensitivityþ speci¢city1).
Table III. Speci¢city of autoantibodies against BP180 and clinical statusa
Extent of disease (n¼114) Disease duration (n¼114) Mucosal involvement (n¼114)
BP180-Nb/Cc Generalized Localized Remittent Acute Chronic Remittent þ ^
^/^ 4 (5.3) 2 (6.1) 0 (0) 2 (2.6) 4 (12.9) 0 (0) 2 (12.5) 4 (4.1)
þ /^ 36 (48.0) 18 (54.5) 5 (83.3) 38 (49.4) 16 (51.6) 5 (83.3) 5 (31.3) 54 (55.1)
^/þ 9 (12.0) 4 (12.1) 0 (0) 9 (11.7) 4 (12.9) 0 (0) 0 (0) 13 (13.3)
þ /þ 26 (34.7) 9 (27.3) 1 (16.7) 28 (36.4) 7 (22.6) 1 (16.7) 9 (56.2) 27 (27.6)
Total 75 (100%) 33 (100%) 6 (100%) 77 (100%) 31 (100%) 6 (100%) 16 (100%) 98 (100%)
p¼ 0.87 p¼ 0.27 p¼ 0.021
ap-values were determined by Fisher’s exact probability test.
bNH2-terminal domain of the ECD of BP180.
cCOOH-terminal domain of the ECD of BP180.
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IgG levels against the NH2-terminus but not against the
COOH-terminus of the ECD of BP180 re£ect severity of
BP Severity of BP was also compared with the OD values
measured by ELISA with the BP180 recombinants, using an
analysis of covariance. As IgG reactivity to either BP180-N or
BP180-C was not detectable in 19 and 66 BP sera, respectively,
we could not establish a signi¢cant relationship between
antibody levels and disease extent when all 114 BP sera were
included in the analysis. If only those sera that were reactive to
the NH2-terminus of the ECD of BP180 (BP180-N, n¼ 95)
were analyzed, however, IgG, IgG1, and IgG4 antibody levels
were signi¢cantly higher in the sera of patients with extensive
skin involvement (n¼ 62) than in the sera of patients with
moderate skin involvement (n¼ 27) or remittent disease (n¼ 6)
(Fig 6, Table IV). Among the sera reactive to the COOH-
terminus of BP180 (BP180-C, n¼ 48), 35 were obtained from
patients with extensive blistering whereas 13 sera were from
patients with a more localized skin phenotype. Comparison of
the two groups showed only marginal di¡erences regarding the
IgG response to BP180-C (p¼ 0.069). A relationship between
disease duration (acute versus chronic disease) and antibody levels
to BP180-N or BP180-C by ELISAwas not observed.
A dual IgG1 and IgG4 response to the NH2-terminus of the
ECD of BP180 is detected predominantly in patients with
severe skin involvement Comparison of the IgG subclass
reactivity with the clinical phenotype of the investigated BP
patients did not reveal any relationship between mucosal
involvement and IgG subclass reactivity against the NH2-
terminus of the ECD of BP180. In contrast, a statistically
signi¢cant relationship was observed between the severity of BP
and IgG isotype reactivity to BP180-N (Fisher’s exact probability
test, p¼ 0.009; Table V). A dual IgG1 and IgG4 response to
BP180-N was detected more frequently in BP patients with
extensive skin involvement than in patients with localized or
remittent BP (Table V). With regard to a potential relationship
between disease duration and isotype speci¢city of anti-BP180-
N antibody (p¼ 0.030), IgG1 reactivity decreased during the
course of disease, whereas IgG4 reactivity showed a tendency to
increase with a longer disease duration. Whereas patients with
acute onset BP showed predominantly IgG1 antibody or a dual
IgG1 and IgG4 response to the NH2-terminus of the ECD of
BP180, an exclusive IgG4 response was detected predominantly
in patients with remittent disease. Comparison of subclass
speci¢city of autoantibodies targeting the COOH-terminus of
BP180 (BP180-C) with phenotype and duration of BP did not
show any relationship (TableVI).
DISCUSSION
The goal of this study was to analyze the relationship between
subclasses and speci¢city of IgG autoantigenes directed against
the ECD of BP180, the putative major autoantibody of BP, and
the clinical phenotype. We developed a novel ELISA utilizing
two eukaryotic proteins of the ECD of BP180 that consisted of
either its NH2-terminal region containing the NC16A and Col15
subdomains (residues 490^811) or its COOH-terminal domain
(residues 1351^1497).
The results demonstrate that the novel ELISA is highly sensi-
tive, as 93% of the 116 sera of patients with active BP examined
Figure 6. The titers of IgG against the NH2-terminus of the BP180
ectodomain are related to the clinical activity of BP. Ninety-¢ve sera
from BP patients reactive to the NH2-terminus of the ECD of BP180
(BP180-N) with generalized (n¼ 62), localized (n¼ 27), and remittent
(n¼ 6) disease were compared with regard to IgG, IgG1, and IgG4 reactiv-
ity against BP180-N using a multivariate analysis of covariance. Sera ob-
tained from BP patients with extensive BP showed signi¢cantly higher
IgG and IgG1 levels than patients with localized or remittent disease.
The di¡erence was not as signi¢cant when sera were analyzed for IgG4
reactivity. Bars indicate the geometric mean (seeTable IV).
Table IV. Comparison of IgG levelsa against the NH2-terminal regions of the BP180 ectodomain (BP180-N)
and clinical activity of BP
Disease activity pb
Ig class Generalized, n¼ 62 Localized, n¼ 27 Remittent, n¼ 6 Generalized versus localized Generalized versus remittent
IgG 0.649 (0.605^0.696) 0.413 (0.372^0.458) 0.272 (0.221^0.335) 0.001 o 0.0001
IgG1 0.768 (0.702^0.840) 0.475 (0.425^0.529) 0.235 (0.211^0.261) 0.001 o0.0001
IgG4 0.322 (0.281^0.368) 0.186 (0.163^0.211) 0.159 (0.137^0.185) 0.007 0.042
aGeometric mean7geometric standard error.
bSigni¢cance of pairwise comparisons within analysis of covariance models with simultaneous adjustment for age and gender.
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showed IgG reactivity with one of the two recombinants of the
ECD of BP180. Speci¢cally, 80% and 47% of the investigated BP
sera contained IgG autoantibodies binding to the NH2-terminal
and the COOH-terminal region of the ECD of BP180, respec-
tively. The NC16A and Col15 domains have been identi¢ed as
harboring major epitopes of BP180 (Giudice et al, 1993; Matsu-
mura et al, 1996; Zillikens et al, 1997b; Schumann et al, 2000)
whereas the COOH-terminus is a major autoantibody binding
site in a subgroup of patients with bullous and cicatricial pemphi-
goid (Balding et al, 1996; Perriard et al, 1999; Schumann et al, 1999).
Previously reported ELISA systems for the detection of autoanti-
bodies speci¢c for de¢ned regions of the ECD of BP180 utilized
prokaryotic BP180 recombinants only (Giudice et al, 1994;
Zillikens et al, 1997a; Nakatani et al, 1998). Zillikens et al detected
IgG reactivity against the NC16A domain of BP180 in 94% of 50
BP sera (Zillikens et al, 1997a). Another ELISA utilizing bacterial
recombinant proteins demonstrated the presence of IgG auto-
antibodies against the NC16A subdomain and the COOH-
extremity of BP180 in 96% and 38% of the BP sera, respectively
(Nakatani et al, 1998). The higher frequency of IgG reactivity
against the COOH-terminal domain of BP180 observed with
our ELISA may depend on several factors. The BP180 recombi-
nant (BP180-C) of this study was expressed in the eukaryotic
baculovirus system that usually provides similar or identical
post-translational modi¢cations to those observed with native
proteins (Kidd and Emery, 1993). Other possible explanations to
be considered include di¡erences in the selection and number of
the investigated BP sera, di¡erential sensitivities and speci¢cities
of the two ELISA systems due to di¡erent cut-o¡ levels, etc. A
direct comparison of the two ELISA systems with identical BP
sera would address some of these points and the question whether
BP sera recognize conformational epitopes of the C-terminal end
of the BP180.
Based on thorough statistical analysis, our ¢ndings demon-
strate that antibody levels against the NH2-terminal region of
the BP180 ECD relate to the severity of BP, whereas the titers of
IgG autoantibodies reactive against its COOH-terminal region
do not. Consistent with previous passive transfer studies with
rabbit sera reactive with the murine homolog of the NC16A do-
main (Liu et al, 1993), our ¢ndings provide further support to the
notion that in ¢rst line antibodies against the NH2-terminal re-
gion of the BP180 ECD are pathogenic. Furthermore, they are
in line with two recent studies suggesting a possible relationship
between disease activity and autoantibody levels against the
NC16A subdomain (D˛pp et al, 2000; Schmidt et al, 2000).
The pathogenic relevance of antibodies against the COOH-
terminus of BP180 has not yet been studied in detail. As BP180
extends from the cytoplasm of the basal keratinocyte to the lami-
na densa (Bedane et al, 1997; Masunaga et al, 1997; Nakatani et al,
1998), it has been speculated that autoantibodies against this re-
gion might be responsible for the scarring phenotype observed
in cicatricial pemphigoid patients. The COOH-terminal end of
BP180 may ^ via its binding to distinct laminin isoforms such as
laminin-5, the autoantigene of a subgroup of cicatricial pemphi-
goid (Egan andYancey 2000) ^ be critically involved in the integ-
rity of the dermo-epidermal junction. Balding et al (1996)
detected reactivity against the COOH-terminus of BP180 in
61% of 23 cicatricial pemphigoid sera by immunoblot analysis.
None of our BP patients that exclusively reacted with the
COOH-terminus of BP180 (15 of 116; 13%) had a scarring phe-
notype of either skin or mucous membranes, however, which is
in line with the ¢nding of a recent independent ELISA study
(Nakatani et al, 1998). It is noteworthy that the majority (56%)
of our BP patients with mucosal involvement showed IgG reac-
tivity against both the NH2- and COOH-terminal regions of the
ECD of BP180, whereas more BP patients without mucosal in-
volvement showed an exclusive IgG reactivity against the NH2-
terminal portion (Table III). Autoantibodies against both the
NH2- and COOH-terminal region of the ECD of BP180 thus
may act synergistically in the development of mucosal lesions.
The ¢ndings of this study clearly demonstrate that autoantibo-
dies against the NH2-terminus of BP180 are predominantly of
the IgG1 class and that their titers relate to the clinical activity of
BP. Previous studies reported a preferential detection of IgG1 and
TableV. Comparison of IgG isotype reactivity against the NH2-terminal region of the BP180 ectodomain (BP180-N)
and the clinical statusa
Extent of disease (n¼ 95) Disease duration (n¼ 95) Mucosal involvement (n¼ 95)
IgG1/IgG4 reactivity Generalized Localized Remittent Acute Chronic Remittent þ ^
^/^ 3 (4.8) 5 (18.5) 1 (16.6) 5 (7.6) 3 (13.0) 1 (16.7) 0 (0) 9 (11.1)
þ /^ 26 (41.9) 14 (51.9) 1 (16.6) 32 (48.5) 8 (34.8) 1 (16.7) 3 (21.4) 38 (46.9)
^/þ 5 (8.1) 1 (3.7) 3 (50.0) 3 (4.5) 3 (13.0) 3 (50.0) 3 (21.4) 6 (7.4)
þ /þ 28 (45.2) 7 (25.9) 1 (16.6) 26 (39.4) 9 (39.2) 1 (16.7) 8 (57.2) 28 (34.6)
Total 62 (100%) 27 (100%) 6 (100%) 66 (100%) 23 (100%) 6 (100%) 14 (100%) 81 (100%)
p¼ 0.009 p¼ 0.030 p¼ 0.063
ap-values were determined by Fisher’s exact probability test.
TableVI. Comparison of IgG isotype reactivity against the COOH-terminus of the BP180 ectodomain (BP180-C)
and the clinical statusa
Extent of disease (n¼ 48) Disease duration (n¼ 48) Mucosal involvement (n¼ 48)
IgG1/IgG4 reactivity Generalized Localized Acute Chronic þ ^
^/^ 6 (17.1) 2 (15.4) 6 (16.2) 2 (18.2) 3 (33.3) 5 (12.8)
þ /^ 5 (14.3) 2 (15.4) 6 (16.2) 1 (9.1) 0 (0) 7 (17.9)
^/þ 2 (5.7) 0 (0) 1 (2.7) 1 (9.1) 1 (11.1) 1 (2.6)
þ /þ 22 (62.9) 9 (69.2) 24 (64.9) 7 (63.6) 5 (55.6) 26 (66.7)
Total 35 (100%) 13 (100%) 37 (100%) 11 (100%) 9 (100%) 49 (100%)
p¼1.00 p¼ 0.76 p¼ 0.14
ap-values were determined by Fisher’s exact probability test.
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IgG4 autoantibodies in BP, whereas BP180-speci¢c IgG2 and
IgG3 antibodies were detected in a minority of BP sera (Bernard
et al, 1990; D˛pp et al, 2000; La⁄tte et al, 2001). As the various IgG
subclasses have distinct functional properties and their secretion is
di¡erentially regulated, we have also assessed the relative isotype
distribution among the major IgG subclasses. The results demon-
strate that 79 of 93 (85%) and 43 of 93 (46%) of the sera con-
tained IgG1 and IgG4 antibodies against the NH2-terminal
region, in contrast to 41 of 54 (76%) and 37 of 54 (69%) of sera
containing IgG1 and IgG4 against the COOH-terminus of the
ECD of BP180, respectively. Our results indicate that a dual
IgG1 and IgG4 response to the NH2-terminus of the ECD of
BP180 is associated with a more severe skin involvement in BP
(Table V). IgG1 against the NH2-terminal portion of the BP180
ECD was predominantly detected in sera of BP patients with
acute onset BP, whereas IgG4 autoantibodies predominated in
sera of BP patients in remission (Table V). In contrast, IgG1 and
IgG4 reactivity to the COOH-terminus of BP180 was indepen-
dent of the clinical activity of BP. Previous studies aiming at the
identi¢cation of IgG subclass reactivity to BP180 showed contro-
versial results.Whereas Bernard et al (1990) found a predominance
of BP180-reactive IgG1 (90% vs 80% IgG4) in 10 BP sera byWes-
tern blot of epidermal extracts, D˛pp et al (2000) detected IgG4
and IgG1 reactivity with the NC16A subdomain in 66% and
50% of 18 BP sera, respectively. In line with our ¢ndings, La⁄tte
et al (2001) recently reported a predominance of IgG1 autoantibo-
dies, as 100% and 77%, respectively, of 27 BP180-reactive BP sera
had IgG1 and IgG4 autoantibodies to the ECD of BP180 by im-
munoblot. The concept that the complement-¢xing IgG1 as the
predominant IgG isotype plays a key role in the initiation of BP
is supported by the clinical ¢nding that, in addition to IgG, C3 is
frequently detected at the dermo-epidermal junction in the peri-
lesional skin of patients with BP (Jordon et al, 1967). Furthermore,
in the murine passive transfer model of BP, subepidermal blister
formation has been found to depend on a functional complement
system (Liu et al, 1995). A recent study in our laboratory has iden-
ti¢ed in BP patients the presence of autoreactive Th1 and Th2
cells, which presumably regulate the secretion of anti-BP180
autoantibodies of the IgG1 and IgG4 subclasses (Bˇdinger et al,
1998).
IgE reactivity to the NH2- and COOH-terminal regions of
the ECD of BP180 was detected in 8% of the BP sera and was
clearly associated with a more severe phenotype of BP as 78%
of the IgE-reactive BP patients had a generalized skin involve-
ment. This is in line with a previous report by Delaporte et al
who detected IgE antibodies against BP230 in patients with
severe BP (Delaporte et al, 1996). A recent ELISA study with a
bacterial NC16A protein detected BP180-reactive IgE in 55% (10
of 18) of selected BP sera (D˛pp et al, 2000). In addition, this ELI-
SA study demonstrates that only 5% of a large cohort of 116 BP
sera contained IgA reactive with these BP180 recombinants; none
of these patients presented with a particular clinical phenotype.
Previous ELISA studies did not detect circulating IgA against
bacterial proteins representing the NC16A and/or COOH-term-
inal domains of BP180 in BP sera (Giudice et al, 1994; Murakami
et al, 1998), whereas in one study IgA reactivity with a bacterial
recombinant form of NC16Awas detected in 65% of 40 BP sera
(Kromminga et al, 2000). This variable prevalence of IgE and IgA
autoantibodies in BP sera may largely depend on the applied
BP180 recombinants, the selected BP patients, and the utilized
test systems (i.e., immunoblot, ELISA).
In summary, our novel ELISA using eukaryotic recombinants
of the NH2- and COOH-terminal regions of the ECD of BP180
is highly useful for rapid and sensitive analysis of the autoanti-
body pro¢le, which re£ects distinct clinical phenotypes of BP.
By this ELISA, we demonstrated that distinct clinical phenotypes
of BP are associated with di¡erential autoantibody responses to
BP180: (i) IgG1 antibodies against the NH2-terminal region of
the ECD of BP180 are predominantly detected in sera of BP
patients with acute BP, whereas IgG4 autoantibodies predominate
in sera of BP patients in remission; (ii) a dual IgG1 and IgG4
response against the NH2-terminal region of the ECD of BP180
is associated with a more severe phenotype of BP; (iii) IgG auto-
antibodies from BP patients with mucosal involvement appear to
target more frequently both the NH2- and COOH-terminal re-
gions of the ECD of BP180; and (iv) IgG autoantibody titers
against the NH2-terminal region but not against the COOH-
terminus of the ECD of BP180 re£ect the extent of skin involve-
ment, supporting the hypothesis that autoantibodies against
the NC16A subdomain of BP180 are critical in the pathogenesis
of BP.
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